Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive after two years compared to 48.6% in the control group. Analysts are optimistic about its potential to transform non-small cell lung cancer therapy and capture a substantial share of the global market, though the company's stock saw a slight dip. AI
